To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.
Able to comprehend and willing to sign a written ICF for the study.
Are 18 years of age or older (or as applicable per local country requirements).
Histologically or cytologically verified, inoperable locally recurrent or metastatic SCAC.
Adequate ECOG performance status to be able to benefit from the treatment.
Has received prior PD-(L)1 directed therapy.
Participants must have recovered from previous therapies for example including but not limited to RT and CRT.
Platelets < 100 × 109/L.
Hemoglobin < 9 g/dL.